---
title: "Weight loss concept stocks are performing strongly! LAEKNA-B surged by over 18%."
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/109303166.md"
description: "LAEKNA-B has announced that the China National Medical Products Administration has accepted the clinical trial application for the new drug LAE102, which can be used to treat adult obesity or metabolic diseases. Huachuang Securities believes that this drug has the potential to be used in combination with GLP-1RA, with huge market potential."
datetime: "2024-03-06T02:07:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/109303166.md)
  - [en](https://longbridge.com/en/news/109303166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/109303166.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/109303166.md) | [繁體中文](https://longbridge.com/zh-HK/news/109303166.md)


# Weight loss concept stocks are performing strongly! LAEKNA-B surged by over 18%.

Zhitong App learned that LAEKNA-B (02105) surged by over 18%, rising by 18.64% at the time of publication to HKD 8.4, with a trading volume of HKD 40.96 million.

On the news front, on Tuesday local time, the manufacturer of the "miracle weight-loss drug" Novo Nordisk AS announced positive progress in treating kidney disease with its widely used semaglutide in a late-stage trial, reducing the risk of kidney disease-related complications by 24%. The drug used in the FLOW trial is Ozempic, mainly for diabetes symptoms, with semaglutide as the active ingredient. The company announced on Tuesday that compared to the placebo group, type 2 diabetes patients treated with semaglutide had a 24% lower risk of kidney failure, chronic kidney disease progression, and complications-related death, achieving the trial's goal.

Of note, Laike Pharmaceuticals previously disclosed that the China National Medical Products Administration's Drug Evaluation Center has accepted the new drug clinical trial application for LAE102, a monoclonal antibody developed independently by Laike targeting ActRIIA for the treatment of adult obesity or metabolic disease patients. The company stated that after obtaining IND approval, they will initiate the clinical trial process. Huachuang Securities previously pointed out that the world's first ActRIIA monoclonal antibody LAE102 can increase muscle mass and reduce fat, has the potential to be used in combination with GLP-1RA, has enormous market potential, and international value.

### 相关股票

- [LAEKNA-B (02105.HK)](https://longbridge.com/zh-CN/quote/02105.HK.md)
- [Global Partners LP (GLP.US)](https://longbridge.com/zh-CN/quote/GLP.US.md)

## 相关资讯与研究

- [Investing legend Mohamed El-Erian says he's avoiding stocks as a demand shock looms for oil](https://longbridge.com/zh-CN/news/281222941.md)
- [Sino Medical Sciences Tech Plans Hong Kong Listing; Shanghai Shares Up 3%](https://longbridge.com/zh-CN/news/281123167.md)
- [Fosun Pharmaceutical to Set Up Parallel Fund Structure](https://longbridge.com/zh-CN/news/281297569.md)
- [Chinese company to use AI-powered testing to boost profits and fast-track IVF](https://longbridge.com/zh-CN/news/280950532.md)
- [In pursuit of profit, India Inc slows R&D as innovation takes back seat](https://longbridge.com/zh-CN/news/281098039.md)